205 related articles for article (PubMed ID: 25518511)
21. Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination.
Cooke GE; Liu-Stratton Y; Ferketich AK; Moeschberger ML; Frid DJ; Magorien RD; Bray PF; Binkley PF; Goldschmidt-Clermont PJ
J Am Coll Cardiol; 2006 Feb; 47(3):541-6. PubMed ID: 16458133
[TBL] [Abstract][Full Text] [Related]
22. [Relevance of CYP2C19 2 regarding platelet reactivity in patients with acute coronary syndrome treated with clopidogrel].
Cano P; Consuegra-Sánchez L; Conesa P; Torres-Moreno D; Jaulent L; Dau D; Picó F; Villegas M
Med Clin (Barc); 2014 Jul; 143(1):6-12. PubMed ID: 23850044
[TBL] [Abstract][Full Text] [Related]
23. Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage.
Kimmelstiel C; Badar J; Covic L; Waxman S; Weintraub A; Jacques S; Kuliopulos A
Thromb Res; 2005; 116(1):55-66. PubMed ID: 15850609
[TBL] [Abstract][Full Text] [Related]
24. Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel.
Lev EI; Patel RT; Guthikonda S; Lopez D; Bray PF; Kleiman NS
Thromb Res; 2007; 119(3):355-60. PubMed ID: 16581111
[TBL] [Abstract][Full Text] [Related]
25. Polyunsaturated omega-3 fatty acids improve responsiveness to clopidogrel after percutaneous coronary intervention in patients with cytochrome P450 2C19 loss-of-function polymorphism.
Gajos G; Zalewski J; Nessler J; Zmudka K; Undas A; Piwowarska W
Kardiol Pol; 2012; 70(5):439-45. PubMed ID: 22623230
[TBL] [Abstract][Full Text] [Related]
26. [Variations in glycoprotein IIb-IIIa (alphaIIb/beta3-integrin) content in healthy donors. Influence on platelet aggregation activity and efficacy of aspirin action].
Khaspekova SG; Sirotkina OV; Shimanova IuV; Mazurov AV
Biomed Khim; 2008; 54(3):361-71. PubMed ID: 18712091
[TBL] [Abstract][Full Text] [Related]
27. [Effect of original and generic clopidogrel on prognosis in relation to different gene polymorphisms].
Mesitskaia DF; Nikitina IuM; Lomakin OV; Shchekochikhin DIu; Kopylov FIu
Ter Arkh; 2014; 86(9):77-82. PubMed ID: 25518510
[TBL] [Abstract][Full Text] [Related]
28. Clopidogrel provides significantly greater inhibition of platelet activity than aspirin when combined with atorvastatin after coronary artery bypass grafting: a prospective randomized study.
Tetik S; Ak K; Isbir S; Eksioglu-Demiralp E; Arsan S; Iqbal O; Yardimci T
Clin Appl Thromb Hemost; 2010 Apr; 16(2):189-98. PubMed ID: 19703819
[TBL] [Abstract][Full Text] [Related]
29. Effects of platelet glycoprotein IIb-IIIa number and glycoprotein IIIa Leu33Pro polymorphism on platelet aggregation and sensitivity to glycoprotein IIb-IIIa antagonists.
Sirotkina OV; Khaspekova SG; Zabotina AM; Shimanova YV; Mazurov AV
Platelets; 2007 Nov; 18(7):506-14. PubMed ID: 17957566
[TBL] [Abstract][Full Text] [Related]
30. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function.
Frelinger AL; Bhatt DL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Lampa M; Brooks JK; Barnard MR; Michelson AD
J Am Coll Cardiol; 2013 Feb; 61(8):872-9. PubMed ID: 23333143
[TBL] [Abstract][Full Text] [Related]
31. PlA(1)/PlA(2) polymorphism does not influence response to Gp IIb-IIIa inhibitors in patients undergoing coronary angioplasty.
Verdoia M; Pergolini P; Camaro C; Restifo M; Rolla R; Schaffer A; Di Giovine G; Marino P; Bellomo G; Suryapranata H; De Luca G;
Blood Coagul Fibrinolysis; 2013 Jun; 24(4):411-8. PubMed ID: 23412353
[TBL] [Abstract][Full Text] [Related]
32. The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy.
Saw J; Densem C; Walsh S; Jokhi P; Starovoytov A; Fox R; Wong G; Buller C; Ricci D; Mancini GB; Fung A
JACC Cardiovasc Interv; 2008 Dec; 1(6):654-9. PubMed ID: 19463380
[TBL] [Abstract][Full Text] [Related]
33. [The effects of cytochrome P450 2C19 genetic polymorphism on clopidogrel resistance and recent prognosis of patients with acute coronary syndrome].
Li SN; Liu Z; Luo Y; Chen PA; Lei XM; Li GL
Zhonghua Nei Ke Za Zhi; 2013 Nov; 52(11):961-5. PubMed ID: 24439192
[TBL] [Abstract][Full Text] [Related]
34. The association of cigarette smoking with enhanced platelet inhibition by clopidogrel.
Bliden KP; Dichiara J; Lawal L; Singla A; Antonino MJ; Baker BA; Bailey WL; Tantry US; Gurbel PA
J Am Coll Cardiol; 2008 Aug; 52(7):531-3. PubMed ID: 18687246
[TBL] [Abstract][Full Text] [Related]
35. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel.
Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Cavallari U; Trabetti E; Sabaté M; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Pignatti PF; Macaya C
Arterioscler Thromb Vasc Biol; 2006 Aug; 26(8):1895-900. PubMed ID: 16645157
[TBL] [Abstract][Full Text] [Related]
36. The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.
Gurbel PA; Bergmeijer TO; Tantry US; ten Berg JM; Angiolillo DJ; James S; Lindahl TL; Svensson P; Jakubowski JA; Brown PB; Duvvuru S; Sundseth S; Walker JR; Small D; Moser BA; Winters KJ; Erlinge D
Thromb Haemost; 2014 Sep; 112(3):589-97. PubMed ID: 25008027
[TBL] [Abstract][Full Text] [Related]
37. Genetic Polymorphism of CYP2C19 and Inhibitory Effects of Ticagrelor and Clopidogrel Towards Post-Percutaneous Coronary Intervention (PCI) Platelet Aggregation in Patients with Acute Coronary Syndromes.
Dong P; Yang X; Bian S
Med Sci Monit; 2016 Dec; 22():4929-4936. PubMed ID: 27977637
[TBL] [Abstract][Full Text] [Related]
38. A Randomized Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Clopidogrel in Three Different CYP2C19 Genotype Groups of Healthy Japanese Subjects.
Kobayashi M; Kajiwara M; Hasegawa S
J Atheroscler Thromb; 2015; 22(11):1186-96. PubMed ID: 26063503
[TBL] [Abstract][Full Text] [Related]
39. [The possibility of selecting optimal antiplatelet therapy in patients with coronary heart disease in terms of CYP2C19 polymorphism].
Bockeria OL; Kudzoeva ZF; Shvarts VA; Koasari AK; Donakanyan SA
Ter Arkh; 2016; 88(5):47-54. PubMed ID: 27239927
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of ADP-induced platelet aggregation by clopidogrel is related to CYP2C19 genetic polymorphisms.
Chen BL; Zhang W; Li Q; Li YL; He YJ; Fan L; Wang LS; Liu ZQ; Zhou HH
Clin Exp Pharmacol Physiol; 2008 Aug; 35(8):904-8. PubMed ID: 18346178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
